美国中西部都市区年轻男性疫苗型人乳头瘤病毒感染率在疫苗引入后六年内下降
研究招募美国中西部都市区14-26岁有性接触男性,分2013-2014年(400人)和2016-2017年(347人)两波调查,检测阴茎、阴囊和肛门HPV。结果显示,至少接种1剂HPV疫苗者比例从23%升至44%,全体男性疫苗型HPV感染率从29%降至20%(OR=0.62),未接种男性从32%降至21%(OR=0.56),接种男性下降21%但无统计学意义,支持疫苗效果和群体保护。
要点
- 全体男性疫苗型HPV感染率从29%降至20%,降幅31%,OR=0.62(95%CI 0.44-0.88)
- 未接种男性疫苗型HPV感染率从32%降至21%,降幅36%,OR=0.56(95%CI 0.34-0.86)
- 接种男性疫苗型HPV感染率下降21%,但无统计学意义;疫苗剂次与感染关联无统计学意义
核心结论
- HPV疫苗推荐后六年,全体、接种和未接种年轻男性疫苗型HPV感染率均下降,支持疫苗效果和群体保护;全体男性疫苗型HPV下降似乎源于未接种男性的下降,提示疫苗的完全效果尚未实现。
研究设计与样本
- 研究为两波数据收集(2013-2014年和2016-2017年),从初级保健诊所、性传播疾病诊所和社区招募14-26岁报告有男女性接触和/或男男性接触的男性,第一波400人,第二波347人;参与者完成问卷并检测阴茎、阴囊和肛门HPV。
主要发现
- 至少接种1剂HPV疫苗的男性比例从第一波的23%升至第二波的44%(p<0.001)。
- 倾向评分加权后,全体男性感染至少1种疫苗型HPV从29%降至20%(下降31%,OR=0.62,95%CI=0.44-0.88)。
- 未接种男性感染至少1种疫苗型HPV从32%降至21%(下降36%,OR=0.56,95%CI=0.34-0.86)。
- 接种男性疫苗型HPV感染下降21%,但无统计学意义;疫苗剂次与HPV感染之间的关联无统计学意义。
关键数值与推荐
- 疫苗型HPV定义为HPV6、11、16和/或18型。
- 全体男性疫苗型HPV感染率从29%降至20%,OR=0.62(95%CI=0.44-0.88)。
- 未接种男性疫苗型HPV感染率从32%降至21%,OR=0.56(95%CI=0.34-0.86)。
- 接种男性疫苗型HPV感染率下降21%,无统计学意义。
临床怎么用
- 作者认为,持续监测和在男性开始性行为前接种疫苗是有必要的。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence. METHODS: Men aged 14-26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013-2014 (N = 400) and 2016-2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression. RESULTS: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44-0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%CI = 0.34-0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant. CONCLUSIONS: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted.
引用
- Widdice LE, Bernstein DI, Franco EL, et al. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. Vaccine. 2019. PMID: 31582269. doi:10.1016/j.vaccine.2019.08.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。